Quantcast

Latest Purdue Pharma L.P. Stories

2014-09-15 08:29:05

STAMFORD, Conn., Sept. 15, 2014 /PRNewswire/ -- Purdue Pharma L.P. today announced that Susie Robinson, former head of human resources at Lumeris, has joined the company as Vice President of Human Resources. http://photos.prnewswire.com/prnvar/20100921/NY67262 "With her proven record of transforming organizations and building talented workforces, Susie will further strengthen Purdue's high performance culture," said Mark Timney, President and CEO of Purdue Pharma. "I'm confident...

2014-09-04 16:27:27

STAMFORD, Conn., Sept. 4, 2014 /PRNewswire/ -- Purdue Pharma is presenting results from several studies and post-hoc analyses evaluating extended-release, single-entity hydrocodone bitartrate tablets, including the analgesic effectiveness and safety among patients transitioning from immediate-release hydrocodone combination products and the formulation's abuse-deterrent potential in recreational opioid abusers at PAINWeek national conference Sept. 2 - 6 in Las Vegas....

2014-08-26 23:00:46

Purdue Pharma L.P. will sponsor the second annual Opioid Awareness Day on Thursday, September 4 at PAINWeek 2014, convening next month in Las Vegas. Montclair, NJ (PRWEB) August 27, 2014 PAINWeek, the National Conference on Pain for Frontline Practitioners, announced today that Purdue Pharma L.P. will sponsor the second annual Opioid Awareness Day on Thursday, September 4 at PAINWeek 2014, convening next month in Las Vegas. The day will feature course offerings, symposia and special...

2014-07-16 08:28:03

FDA also approves the use of two Butrans patches for dose adjustments in appropriate chronic pain patients STAMFORD, Conn., July 16, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) approved a new 7.5 mcg/hour dosage strength of Butrans(®) (buprenorphine) Transdermal System CIII. Five strengths of Butrans will now be available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. The Butrans Transdermal System is also...

2014-07-08 08:31:18

Anticipated FDA action set for October 2014 STAMFORD, Conn., July 8, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) has granted Priority Review designation for the company's once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse by...

2014-06-18 08:29:38

Agreement renews and expands partnership to drive continued business value from infrastructure and application operations SUNNYVALE, California, June 18, 2014 /PRNewswire/ -- HCL Technologies Ltd [http://www.hcltech.com ]. (HCL), a global IT services provider, today announced that its customer, Purdue Pharma L.P [http://www.purduepharma.com ], a leading pharmaceutical company has extended its end-to-end IT Infrastructure Management engagement with HCL, marking an important...

2014-05-27 12:31:59

LONDON, May 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Pain Management Drugs Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/therapeutic/global_pain_management_drugs_market_2014_2018.html TechNavio's analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The...

2014-05-22 08:28:50

STAMFORD, Conn., May 22, 2014 /PRNewswire/ -- Purdue Pharma L.P. today announced that Saeed Motahari has joined the company as Senior Vice President and Chief Commercial Officer. "We welcome Saeed to the Purdue team. I am confident that his impressive capabilities will strengthen our organization," said Mark Timney, President and CEO of Purdue Pharma. "Saeed's experience and expertise make him uniquely qualified to lead our commercial efforts." Saeed has more than 20 years of...

2014-04-30 08:33:23

Data from Clinical Drug-liking Studies Also to be Presented at APS Today STAMFORD, Conn., April 30, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) seeking authorization to market a once-daily, single-entity hydrocodone bitartrate tablet (HYD). This investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate...

2014-04-29 12:33:30

STAMFORD, Conn., April 29, 2014 /PRNewswire/ -- Purdue Pharma L.P. will present results from a number of research studies at the American Pain Society (APS) 33(rd) Annual Scientific Meeting, April 30-May 3, 2014, in Tampa, Fla. Following is a schedule of select poster presentations: Authors Date / Time Title...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related